French (CAC) Healthcare Sector Analysis

Sector Valuation and Performance

Has the French Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 14 Jul 2026	€246.7b	€117.9b	€7.4b	19.2x	33.4x	2.1x
Thu, 11 Jun 2026	€243.6b	€117.9b	€7.4b	18.6x	32.9x	2.1x
Sat, 09 May 2026	€237.9b	€117.9b	€7.4b	19.1x	32.1x	2x
Mon, 06 Apr 2026	€264.6b	€117.2b	€7.4b	19.7x	35.6x	2.3x
Wed, 04 Mar 2026	€270.5b	€117.1b	€7.7b	21.3x	35.1x	2.3x
Fri, 30 Jan 2026	€286.2b	€114.7b	€9.2b	22.2x	31.2x	2.5x
Sun, 28 Dec 2025	€301.0b	€114.8b	€9.2b	21.1x	32.6x	2.6x
Tue, 25 Nov 2025	€310.6b	€114.8b	€9.5b	20.5x	32.7x	2.7x
Thu, 23 Oct 2025	€317.8b	€114.7b	€9.5b	20.9x	33.5x	2.8x
Sat, 20 Sep 2025	€290.0b	€114.6b	€9.3b	21x	31.2x	2.5x
Mon, 18 Aug 2025	€294.7b	€114.3b	€9.3b	20.7x	31.6x	2.6x
Wed, 16 Jul 2025	€278.6b	€112.6b	€9.0b	22.9x	30.9x	2.5x
Fri, 13 Jun 2025	€287.6b	€112.6b	€9.0b	24.1x	32x	2.6x
Sun, 11 May 2025	€288.9b	€112.6b	€8.8b	23.6x	32.8x	2.6x
Tue, 08 Apr 2025	€274.7b	€111.3b	€10.1b	19.4x	27.2x	2.5x
Thu, 06 Mar 2025	€328.6b	€111.1b	€10.1b	24.8x	32.5x	3x
Sat, 01 Feb 2025	€318.2b	€110.0b	€10.3b	20.8x	30.8x	2.9x
Mon, 30 Dec 2024	€284.4b	€113.9b	€9.1b	21.8x	31.3x	2.5x
Wed, 27 Nov 2024	€279.0b	€113.9b	€9.1b	20x	30.8x	2.4x
Fri, 25 Oct 2024	€284.4b	€112.5b	€8.8b	22.3x	32.3x	2.5x
Sun, 22 Sep 2024	€284.8b	€112.2b	€8.6b	21.5x	33.1x	2.5x
Tue, 20 Aug 2024	€281.4b	€111.8b	€8.6b	23.1x	32.8x	2.5x
Thu, 18 Jul 2024	€262.5b	€110.1b	€9.0b	24x	29x	2.4x
Sat, 15 Jun 2024	€262.2b	€110.0b	€9.0b	21.5x	29.1x	2.4x
Mon, 13 May 2024	€278.3b	€110.0b	€9.0b	23.8x	30.9x	2.5x
Wed, 10 Apr 2024	€272.1b	€104.7b	€8.5b	20.5x	31.9x	2.6x
Fri, 08 Mar 2024	€271.6b	€104.7b	€8.5b	21.3x	31.8x	2.6x
Sun, 04 Feb 2024	€257.7b	€104.8b	€9.0b	21.4x	28.5x	2.5x
Tue, 02 Jan 2024	€262.1b	€104.0b	€12.7b	21.6x	20.6x	2.5x
Thu, 30 Nov 2023	€248.6b	€104.0b	€12.7b	20.6x	19.6x	2.4x
Sat, 28 Oct 2023	€234.5b	€104.6b	€12.4b	20.8x	19x	2.2x
Mon, 25 Sep 2023	€272.0b	€104.9b	€12.5b	23.6x	21.8x	2.6x
Wed, 23 Aug 2023	€274.5b	€104.5b	€12.5b	22x	22x	2.6x
Fri, 21 Jul 2023	€270.8b	€103.8b	€12.4b	19.5x	21.8x	2.6x

Current Industry PE

Investors are optimistic on the French Healthcare industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 33.3x which is higher than its 3-year average PE of 30.1x.

The 3-year average PS ratio of 2.5x is higher than the industry's current PS ratio of 2.1x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have declined 16% per year over the last three years.
Meanwhile revenues for these companies have grown 4.4% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the French Healthcare sector?


FR Market	-1.28%
Healthcare	0.57%
Life Sciences	3.72%
Pharma	2.22%
Healthtech	0.0088%
Medical Equipment	-1.31%
Healthcare Services	-2.04%
Biotech	-5.94%

Industry PE

Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 47.2x.

Analysts are expecting annual earnings growth of 19.5%, which is higher than its past year's earnings growth of 16.8% per year.

Forecasted Growth

Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 60% over the next 5 years.
This is better than its past earnings decline of 39% per year.

In contrast, the Medical Equipment industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
SAN Sanofi	€77.10	3.5% +€3.1b	-7.7%	PE19.2x
DIM Sartorius Stedim Biotech	€189.30	5.5% +€963.2m	-3.5%	PE68.7x
CVX Carvolix	€7.16	62.7% +€163.5m	450.8%	PS471.3x
BIM bioMérieux	€70.85	1.9% +€153.3m	-40.8%	PE21x
ERF Eurofins Scientific	€69.50	1.2% +€139.8m	15.5%	PE29.2x

Cellectis S.A. Presents Final Phase 1 Results of Lasme-Cel and Preliminary Results on Eti-Cel At Eha 2026 Congress

Cellectis S.A. presented final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association 2026 Annual Congress. 45 patients in third line and beyond (3L+) were treated in the BALLI-01 study. 15 patients were treated at the recommended Phase 2 dose and 7 in the target Phase 2 population. Patients were heavily pretreated with those in the target Phase 2 population receiving a median of 5 prior lines of therapy (Range 2-11). Almost all patients were previously treated with blinatumumab (82%) and were also heavily exposed to CD19 CAR-T (53%), CD22-directed antibody-drug conjugate (ADC) (56%) and many had a prior hematopoietic stem cell transplantation (HSCT) (47%). In the target Phase 2 population, an overall response rate (ORR) of 100% (7/7) was achieved with a complete remission/complete remission with incomplete count recovery (CR/CRi) rate of 57% (4/7). Of these, 75% achieved minimal residual disease negative (MRD-ve) status. All patients subsequently proceeded to HSCT. Lasme-cel demonstrated a manageable safety profile. Cytokine release syndrome (CRS) grade 3 occurred in 4% of patients. Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 3 occurred in 4% of patients. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) grade 3 occurred in 2% of patients. All CRS, ICANS, and IEC-HS resolved. The Pivotal Phase 2 BALLI-01 trial is open for recruitment. The first interim analysis is expected in Fourth Quarter 2026. Oral Presentation: Safety and efficacy of UCART22 in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL): results of the Phase 1 BALLI-01 trial. Date/Time: Saturday, June 13 at 5:15 - 6:30pm, local time. Session Title: Advances in the treatment of lymphoblastic leukemia. Session Room: K1. Abstract Number: 4689. Note: presentation slides will be uploaded to Cellectis' website concurrently with the live presentation. The NATHALI-01 preliminary data on the role of alemtuzumab in optimizing responses will be presented as a poster by Professor Emmanuel Bachy, M.D., Ph.D., Department of Hematology, Hospices Civils de Lyon, France. Eti-cel is a highly differentiated product being the first allogeneic dual CAR-T targeting both CD20 and CD22, for patients with r/r B-NHL. As of the February 2026 data cutoff, 14 patients with r/r B-NHL had been treated across three dose levels, in a heavily pre-treated population with a median of 3 prior lines of therapy, 93% of whom had received prior CD19-directed CAR-T therapy, and all of whom presented with stage IV disease at baseline. In the optimal dose cohort, ORR and complete response (CR) were 88% and 63%, respectively. The analysis identified a positive correlation between alemtuzumab exposure and clinical outcomes: higher alemtuzumab exposure created a favorable lower inflammatory homeostatic milieu prior to eti-cel infusion and was associated with enhanced eti-cel expansion and higher response rates. Additionally, responders maintained sustained low-level interleukin 2 (IL-2) secretion when compared to non-responders. These findings provide a scientific rationale for the implementation of a weight-based alemtuzumab dosing regimen, currently under investigation to optimize lymphodepletion. Additionally, subcutaneous low-dose IL-2 is being investigated to further enhance eti-cel expansion and treatment response. The NATHALI-01 study is open for recruitment with the full Phase 1 clinical data expected in Fourth Quarter 2026. Poster Presentation: Alemtuzumab exposure and sustained IL-2 drive UCART20x22 expansion and clinical response in adults with relapsed or refractory B-cell non-Hodgkin lymphoma: NATHALI-01 study. Date/Time: Saturday, June 13 at 6:45 - 7:45pm, local time. Session: Poster Session 2. Poster Number: 4758. Note: poster presentation will be uploaded to Cellectis' website at the opening of the poster session.

French (CAC) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

FDA Approves Sanofi’s Sarclisa Escena as First Cancer Drug via On-Body Injector

Inventiva Finalizes EIB Warrant Restructuring to Simplify Capital Structure

BIM: Regulatory Pipeline Progress Will Drive Future Reassessment Of Recent Downgrades

EMEIS: Strengthened Governance And Stabilized Finances Will Support Future Re rating

Dysport Hits Phase III Migraine Milestone With Significant Reduction in Monthly Attacks

Eurofins Scientific SE to Report First Half, 2026 Results on Jul 23, 2026

Price target decreased by 7.2% to €251

New major risk - Shareholder dilution

MEDCL: Fair Outlook Balances Regulatory Milestone Prospects With Execution And Funding Risks

Now 50% overvalued after recent price rise

CLARI: Hybrid Notes Refinancing Will Test Support For Elevated Future P/E

DIM: Bioprocessing Recovery Signals Will Support Constructive Outlook Despite Higher Sector Risk

Carvolix Announces Positive Three-Year Clinical Results for Kalios Adjustable Mitral Ring

Cellectis S.A. Presents Final Phase 1 Results of Lasme-Cel and Preliminary Results on Eti-Cel At Eha 2026 Congress

Dividend increased to €0.93

Ramsay Générale de Santé SA's (EPA:GDS) Price In Tune With Revenues